Insider Selling: Liquidia Co. (NASDAQ:LQDA) CFO Sells $12,557.41 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 1,091 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $11.51, for a total transaction of $12,557.41. Following the completion of the sale, the chief financial officer now owns 312,328 shares of the company’s stock, valued at approximately $3,594,895.28. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, October 14th, Michael Kaseta sold 3,892 shares of Liquidia stock. The shares were sold at an average price of $11.11, for a total value of $43,240.12.

Liquidia Stock Up 3.5 %

Liquidia stock opened at $11.48 on Friday. The stock has a market capitalization of $971.67 million, a price-to-earnings ratio of -7.04 and a beta of 0.22. The stock has a 50-day simple moving average of $10.82 and a 200 day simple moving average of $11.33. Liquidia Co. has a 12-month low of $6.85 and a 12-month high of $16.99.

Analysts Set New Price Targets

A number of research firms have weighed in on LQDA. Lifesci Capital started coverage on shares of Liquidia in a research note on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. Bank of America lowered their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. BTIG Research cut their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Finally, Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. California State Teachers Retirement System increased its position in Liquidia by 491.2% in the first quarter. California State Teachers Retirement System now owns 46,181 shares of the company’s stock worth $681,000 after purchasing an additional 38,369 shares during the period. Boston Partners acquired a new stake in shares of Liquidia during the 1st quarter worth approximately $762,000. Marshall Wace LLP bought a new stake in shares of Liquidia during the second quarter worth approximately $545,000. Sapient Capital LLC acquired a new position in Liquidia in the third quarter valued at approximately $1,336,000. Finally, HighVista Strategies LLC acquired a new stake in Liquidia during the 2nd quarter worth $1,461,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).